Teikoku to decide future of Aricept patch alone as it pulls US NDA
This article was originally published in Scrip
Executive Summary
Teikoku Seiyaku has decided to withdraw a US new drug application for a transdermal patch formulation of Eisai's Alzheimer's disease drug Aricept (donepezil), following the rejection of the product by the FDA around a year ago.